Bio tech company updates — 5/25/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korea's biotech sector continues to attract global attention, with Korean-American firm Ingenia Therapeutics securing KOSDAQ listing approval and its lead drug entering Phase 3 trials. Meanwhile, experts are warning that Korea must act more aggressively as China rapidly gains ground in the global biotech race. Korea's National Growth Fund — which includes biotech among its target sectors — sold out on its first day, signaling strong investor appetite.
Key Findings
-
Ingenia Therapeutics, a Korean-American biotech, has received approval to list on KOSDAQ. Its lead asset, the TIE2-activating drug MK-8748 — licensed to MSD (Merck) — has recently entered Phase 3 clinical trials for wet age-related macular degeneration (AMD).
-
Industry observers are sounding the alarm that Korea must move more aggressively in biotech investment as the U.S. biotech funding environment rebounds from its winter, but China is emerging as a formidable competitor threatening Korea's position.
-
Korea's National Growth Fund, which targets strategic growth industries including biotech, sold out on its first day with 600 billion won cleared at major banks and brokerages, prompting authorities to weigh a second tranche.
Details
Ingenia Therapeutics Wins KOSDAQ Approval
Korean-American biotech Ingenia Therapeutics has cleared a significant milestone, receiving KOSDAQ listing approval. The company's flagship compound, MK-8748, is a TIE2-activating drug that was licensed to pharmaceutical giant MSD. The drug has recently advanced into Phase 3 clinical trials for wet AMD, a leading cause of vision loss in older adults. This listing represents a growing trend of cross-border Korean biotech ventures seeking capital through Korea's tech-focused stock exchange.
Korea Warned to Act More Aggressively as China Gains Ground
A recent expert interview published by TheBioNews warns that while the global biotech funding winter is nearing its end, the recovery will not be evenly distributed. China has emerged as a formidable competitor, and Korea risks falling behind if it does not scale its investment and strategic ambitions more decisively. The piece underscores an urgent need for Korea to differentiate its biotech pipeline and accelerate partnerships with global pharmaceutical leaders.
National Growth Fund Sells Out — Second Tranche Under Consideration
Korea's National Growth Fund was met with overwhelming demand on its launch day, with 600 billion won fully subscribed at major banks and brokerages within hours. The strong retail and institutional interest has prompted Korean authorities to actively weigh issuing a second tranche of the fund. While not exclusively biotech-focused, the fund targets high-growth national industries — a category that prominently includes Korea's expanding life sciences sector.
Sources
- Seoul Economic Daily — Ingenia Therapeutics KOSDAQ Approval:
- TheBioNews — Korea Biotech Investment Warning:
- Seoul Economic Daily — Korea National Growth Fund Second Tranche:
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
